FDA Classifies Non-Bug Infection Spotter Device
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting devices that detect and measure non-microbial markers to find localized infections into a safer, more manageable category called Class II. This change, effective May 9, 2025, means these devices will face fewer regulatory hurdles, making it easier and faster for patients to get access to new, helpful infection-detecting tools. Companies making these devices will now follow special safety rules but avoid the toughest approval process, saving time and money.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Faster patient access to new infection tests
FDA is classifying devices that detect and measure non-microbial markers to help find localized human infections as Class II (special controls), effective May 9, 2025 (classification applicable May 23, 2019). FDA says this classification will reduce regulatory burdens and enhance patients' access to beneficial innovative devices.
Manufacturers can use 510(k) pathway
Because FDA has classified this device type into Class II via De Novo, the device can serve as a predicate for future devices and sponsors can use the less-burdensome 510(k) premarket notification process instead of premarket approval. The order codifies the device type at 21 CFR 866.3230 and states the device is subject to premarket notification under section 510(k).
Mandatory labeling to prevent misinterpretation
Manufacturers must include specific labeling under 21 CFR 866.3230, such as a detailed intended use, performance characteristics, interpretation guidance, and limiting statements including that a negative test result does not preclude infection and that results should be interpreted with other clinical and laboratory data.
Required studies, validation, and training for makers
The special controls require manufacturers to provide detailed design descriptions, analytical performance documentation (e.g., limits of detection/quantitation), clinical study data comparing performance to an FDA-accepted reference or comparator, evaluation of analyte levels in asymptomatic patients, end-user training programs, risk mitigation strategies, and software impact descriptions as part of premarket submissions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies
The FDA is officially putting the DNA-based test that checks for tiny amounts of leftover cancer cells in blood cancers into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while making it simpler for companies to get it to patients faster. The new rules started on May 9, 2025, and could speed up access to this important test without extra costs.
Next: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device
The FDA is officially putting microbial nucleic acid storage and stabilization devices into class II, meaning they’ll have special safety rules but less red tape. This change helps companies bring these devices to market faster while keeping patients safe. It affects manufacturers and healthcare providers starting May 9, 2025, and aims to boost innovation without extra costs.